Dyne Therapeutics

A team at Atlas Venture began working on how to deliver small interfering RNA (siRNA) to the kidney three years ago and created a platform similar to technologies that have emerged for delivering olig

With a US Food and Drug Administration partial clinical hold lifted, Avidity Biosciences, Inc. is moving forward with a Phase III trial of its antibody-oligonucleotide conjugate (AOC) candidate delp

A recent conference in China spotlighted trends around diversification of bioconjugates, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) seen leading the novel

The drug development focus in Duchenne muscular dystrophy (DMD) has been on gene therapy recently, but Dyne Therapeutics is working to develop next-generation exon-skipping medications that would co